Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways

被引:32
作者
Ellebrecht, Christoph T. [1 ]
Maseda, Damian [1 ]
Payne, Aimee S. [1 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Dermatol, 421 Curie Blvd, Philadelphia, PA 19104 USA
关键词
LINKED-IMMUNOSORBENT-ASSAY; DESMOGLEIN; MONOCLONAL-ANTIBODY; COMPLEMENT ACTIVATION; BLISTER FORMATION; FOLIACEUS PF; B-CELLS; VULGARIS; AUTOANTIBODIES; AUTOIMMUNE;
D O I
10.1016/j.jid.2021.04.040
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Pemphigus and pemphigoid are paradigms for understanding the mechanisms of antibody-mediated autoimmune disease in humans. In pemphigus, IgG4-predominant autoantibodies cause intraepidermal blistering by direct interference with desmoglein interactions and subsequent disruption of desmosomes and signaling pathways. In pemphigoid, IgG1, IgG4, and IgE autoantibodies against basement membrane zone antigens directly interfere with hemidesmosomal adhesion, activating complement and Fc receptor-mediated effector pathways. Unraveling disease mechanisms in pemphigus and pemphigoid has identified numerous opportunities for clinical trials, which hold promise to identify safer and more effective therapies for these potentially life-threatening diseases.
引用
收藏
页码:907 / 914
页数:8
相关论文
共 105 条
[1]   Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series [J].
Abdat, Rana ;
Waldman, Reid A. ;
de Bedout, Valeria ;
Czernik, Annette ;
Mcleod, Michael ;
King, Brett ;
Gordon, Samantha ;
Ahmed, Razzaque ;
Nichols, Anna ;
Rothe, Marti ;
Rosmarin, David .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (01) :46-52
[2]  
Amagai M, 1999, BRIT J DERMATOL, V140, P351
[3]   A randomized double-blind trial of intravenous immunoglobulin for pemphigus [J].
Amagai, Masayuki ;
Ikeda, Shigaku ;
Shimizu, Hiroshi ;
Iizuka, Hajime ;
Hanada, Katsumi ;
Aiba, Setsuya ;
Kaneko, Fumio ;
Izaki, Seiichi ;
Tamaki, Kunihiko ;
Ikezawa, Zenro ;
Takigawa, Masahiro ;
Seishima, Mariko ;
Tanaka, Toshihiro ;
Miyachi, Yoshiki ;
Katayama, Ichiro ;
Horiguchi, Yuji ;
Miyagawa, Sachiko ;
Furukawa, Fukumi ;
Iwatsuki, Keiji ;
Hide, Michihiro ;
Tokura, Yoshiki ;
Furue, Masutaka ;
Hashimoto, Takashi ;
Ihn, Hironobu ;
Fujiwara, Sakuhei ;
Nishikawa, Takeji ;
Ogawa, Hideoki ;
Kitajima, Yasuo ;
Hashimoto, Koji .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (04) :595-603
[4]  
ANHALT GJ, 1986, J IMMUNOL, V137, P2835
[5]  
[Anonymous], 2020, RITUXAN PACKAGE INSE
[6]   p38MAPK inhibition prevents disease in pemphigus vulgaris mice [J].
Berkowitz, Paula ;
Hu, Peiqi ;
Warren, Simon ;
Liu, Zhi ;
Diaz, Luis A. ;
Rubenstein, David S. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (34) :12855-12860
[7]   Production of non-pathogenic human monoclonal antibodies to desmoglein 3 from pemphigus vulgaris patient [J].
Bhol, KC ;
Ahmed, AR .
AUTOIMMUNITY, 2002, 35 (02) :87-91
[8]   Milestones in Personalized Medicine in Pemphigus and Pemphigoid [J].
Bieber, Katja ;
Kridin, Khalaf ;
Emtenani, Shirin ;
Boch, Katharina ;
Schmidt, Enno ;
Ludwig, Ralf J. .
FRONTIERS IN IMMUNOLOGY, 2021, 11
[9]   Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses [J].
Blumberg, L. J. ;
Humphries, J. E. ;
Jones, S. D. ;
Pearce, L. B. ;
Holgate, R. ;
Hearn, A. ;
Cheung, J. ;
Mahmood, A. ;
Del Tito, B. ;
Graydon, J. S. ;
Stolz, L. E. ;
Bitonti, A. ;
Purohit, S. ;
de Graaf, D. ;
Kacena, K. ;
Andersen, J. T. ;
Christianson, G. J. ;
Roopenian, D. C. ;
Hubbard, J. J. ;
Gandhi, A. K. ;
Lasseter, K. ;
Pyzik, M. ;
Blumberg, R. S. .
SCIENCE ADVANCES, 2019, 5 (12)
[10]   IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid [J].
Chakievska, Lenche ;
Holtsche, Maike M. ;
Kuenstner, Axel ;
Goletz, Stephanie ;
Petersen, Britt-Sabina ;
Thaci, Diamant ;
Ibrahim, Saleh M. ;
Ludwig, Ralf J. ;
Franke, Andre ;
Sadik, Christian D. ;
Zillikens, Detlef ;
Hoelscher, Christoph ;
Busch, Hauke ;
Schmidt, Enno .
JOURNAL OF AUTOIMMUNITY, 2019, 96 :104-112